Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

JAGX

J

Jaguar Health, Inc. (JAGX)

NCM – Real Time Price. Currency in USD

0.34

-0.05 (-12.64%)

At close: Mar 27, 2026, 4:00 PM EDT

0.35

+0.00 (0.73%)

After-hours: Mar 27, 2026, 7:59 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

MVID has a lethal natural history requiring life-sustaining parenteral support (PS), which includes total parenteral nutrition (TPN), which is associated with significant toxicities; PS reduction could potentially reduce co-morbidities and improve clinical benefit, as no approved therapies exist for MVID Jaguar launches news alert text service for investors - click here to sign up for text alerts SAN FRANCISCO, CA / ACCESS Newswire / March 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that, based on the U.S. Food and Drug Administration (FDA) support for Napo's protocol amendment for its clinical trial to evaluate the safety and efficacy of its novel crofelemer powder-for-oral-solution formulation in pediatric patients with intestinal failure due to MVID, an ultrarare pediatric disorder, Napo plans to initiate a single-blind extension phase for the trial. The extended treatment period has the potential to improve clinical benefit of crofelemer through reduction of parenteral support (PS) requirements, which may result in disease progression-modification of MVID.

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Magdalena Biosciences ("Magdalena"), a US-based joint venture formed by Jaguar and Canada-based Filament Health Corp. (OTC:FLHLF) ("Filament"), has initiated a preclinical study evaluating the effectiveness of a whole leaf coca extract for appetite suppression. The coca leaf extract is Magdalena's drug candidate for post-GLP-1 weight loss management.

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March 12, 2026 at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com. Participation Instructions for Jaguar's Virtual Presentation at the Life Sciences Investor Forum When: Thursday, March 12, 2026 at 2:00 PM Eastern Registration link for conference: Click Here Replay: A replay of the webcast will be available following the conclusion of the conference.

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Strengthening balance sheet and capitalization is a key Jaguar priority Company continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure indications SAN FRANCISCO, CA / ACCESS Newswire / March 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that the Company has strengthened its balance sheet by restructuring and reducing its royalty obligations and debt held by affiliates of Chicago Venture Partners L.P., including the extinguishment of 48,212 warrants.

Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

As announced , Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure indications SAN FRANCISCO, CA / ACCESS Newswire / March 3, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that its wholly-owned subsidiary Napo Pharmaceuticals, Inc. (collectively, with Jaguar Health, Inc., "Jaguar") has received a $3 million payment from Future Pak, LLC ("Future Pak") following termination by Jaguar of the buy-back provision of the U.S. licensing agreement Jaguar entered in January 2026 with a Future Pak affiliate, which allows Future Pak to continue to commercialize Mytesi beyond five years. Jaguar will continue to manufacture Mytesi and Canalevia-CA1 for Future Pak.

Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend

Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend

Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / March 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today issued a reminder that today, March 2, 2026, is the Record Date for the Company's one-time special stock dividend (the "Special Stock Dividend"). As announced, in February 2026 Jaguar's Board of Directors declared a one-time Special Stock Dividend to holders of Jaguar Common Stock and certain outstanding warrants as of record on March 2, 2026.

Jaguar Health Announces a Special One-time Stock Dividend

Jaguar Health Announces a Special One-time Stock Dividend

Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a one-time special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock and certain outstanding warrants as of record on March 2, 2026. The Special Stock Dividend will consist of the Company's Series O Convertible Preferred Stock (the "Preferred Stock").

Videos

No Data

There is no data to display

Press releases

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

MVID has a lethal natural history requiring life-sustaining parenteral support (PS), which includes total parenteral nutrition (TPN), which is associated with significant toxicities; PS reduction could potentially reduce co-morbidities and improve clinical benefit, as no approved therapies exist for MVID Jaguar launches news alert text service for investors - click here to sign up for text alerts SAN FRANCISCO, CA / ACCESS Newswire / March 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that, based on the U.S. Food and Drug Administration (FDA) support for Napo's protocol amendment for its clinical trial to evaluate the safety and efficacy of its novel crofelemer powder-for-oral-solution formulation in pediatric patients with intestinal failure due to MVID, an ultrarare pediatric disorder, Napo plans to initiate a single-blind extension phase for the trial. The extended treatment period has the potential to improve clinical benefit of crofelemer through reduction of parenteral support (PS) requirements, which may result in disease progression-modification of MVID.

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Magdalena Biosciences ("Magdalena"), a US-based joint venture formed by Jaguar and Canada-based Filament Health Corp. (OTC:FLHLF) ("Filament"), has initiated a preclinical study evaluating the effectiveness of a whole leaf coca extract for appetite suppression. The coca leaf extract is Magdalena's drug candidate for post-GLP-1 weight loss management.

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March 12, 2026 at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com. Participation Instructions for Jaguar's Virtual Presentation at the Life Sciences Investor Forum When: Thursday, March 12, 2026 at 2:00 PM Eastern Registration link for conference: Click Here Replay: A replay of the webcast will be available following the conclusion of the conference.

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Strengthening balance sheet and capitalization is a key Jaguar priority Company continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure indications SAN FRANCISCO, CA / ACCESS Newswire / March 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that the Company has strengthened its balance sheet by restructuring and reducing its royalty obligations and debt held by affiliates of Chicago Venture Partners L.P., including the extinguishment of 48,212 warrants.